News room

Latest news and updates

We are engaged in multiple public, private, and academic clinical projects on a daily basis, contributing to the development of innovative medical solutions to those in need. Here, we publish news and highlights of our projects and activities, offering you an up-to-date perspective on our company.

March 26, 2024

InnoSer partners with CR2O to offer an integrated drug discovery to clinical trials pipeline

Prepare for a game-changing collaboration! InnoSer and CR2O unveil their strategic partnership, bridging the gap between pre-clinical and clinical research. Join us as we revolutionize drug discovery and development with an integrated platform poised to accelerate groundbreaking treatments to market. Read the full press release unveiling this transformative alliance!
Read More
, ,
February 15, 2024

Biointelect and CR2O forge new strategic partnership to provide advanced end-to-end commercialisation solutions for the life science sector globally

Driving more efficient and accelerated results from pre-clinical trials to commercialisation of new therapies for Australian, European and U.S. firms. The full innovation journey offering for Biointelect, a strategic life science consulting company, and CR2O, a leading contract research organisation, has reached new heights, with Australian, European and U.S. clients now able to tap into world-class strategic advice and full-service...
Read More
, , ,
October 10, 2023

CEPI to invest up to $25.9 million, with support from the EU, in trials in East Africa to assess a vaccine candidate against Rift Valley Fever (RVF) in people most at risk of infection

The Coalition for Epidemic Preparedness Innovations (CEPI) is expanding its partnership with Wageningen Bioveterinary Research (WBVR) to advance WBVR’s vaccine candidate against Rift Valley fever (RVF) through a multi-site Phase I/IIa clinical trial. Subject to regulatory and ethical approvals, the anticipated trials are scheduled to begin in 2025 in Kenya and Uganda, two countries where the mosquito-borne disease poses a...
Read More
, , , ,
May 21, 2023

CR2O and Artemis Bioservices successfully continue their well-established cooperation

CR2O is a leading European clinical CRO, specialised in managing and operating early-stage infectious disease clinical trials. Artemis Bioservices is a specialty lab, evaluating viral vaccines and antiviral therapeutics, in particular against emerging, zoonotic and vector-borne diseases. For several years, CR2O and Artemis Bioservices have teamed up to advance industry- and public partners’ compounds from bench to various stages of...
Read More
,
March 29, 2023

CR2O and 3D-PharmXchange are celebrating and securing their successful ongoing collaboration

A successful drug development strategy is a well-designed and dynamic process. Making sure regulatory requirements are embedded from the start, is key. From pre-clinical all the way to registration, a well-organized set of action plans needs to be in place that guides and accelerates the client’s vision on how to support their targeted therapeutic area. CR2O (cr2o.nl) and 3D-PharmXchange (3d-pxc.com)...
Read More
,
January 26, 2023

Initiation of the First-in-Human trial with Dyadic’s SARS-CoV-2-RBD vaccine candidate DYAI-100

CR2O is happy to announce that the First-in-Human trial with Dyadic’s SARS-CoV-2-RBD vaccine candidate DYAI-100 has started in South Africa. Dyadic International Inc. is a global biotechnology company focused on further improving, applying and deploying its proprietary C1-cell protein production platform to accelerate development, lower production costs and improve the performance of biologic vaccines and drugs at flexible commercial scales....
Read More
, , , , ,
August 24, 2022

LARISSA consortium reaches milestone: Novel Rift Valley fever vaccine dosed in Phase I human trial

The first healthy volunteer was dosed with hRVFV-4s, a novel live-attenuated Rift Valley fever vaccine. A clinical trial, run by the LARISSA[1] consortium and which started this week, will assess the safety, tolerability and immunogenicity of the vaccine candidate. “We are very proud and excited to have reached this milestone,” says Carine Punt, CEO of WUR Spin-out BunyaVax, the company...
Read More
, , , , ,
July 29, 2022

First clinical trial authorisation under ECTR is a fact

The clinical trial application of the LARISSA study is the first application submitted successfully by CR2O under the new European Clinical Trial Regulation (ECTR). The ECTR is the new regulation for receiving ethical and regulatory approval in the European Union and European Economic Area by using the Clinical Trial Information System (CTIS) centralized portal to submit clinical trial applications. LARISSA...
Read More
, , ,
April 22, 2022

Freya Pharma Solutions to start pivotal Phase III study with CR2O as clinical operational partner

Freya Pharma Solutions, a late clinical stage company focusing on the development of effective pharmaceutical therapies for women who have been diagnosed with Female Sexual Interest/Arousal Disorder (FSIAD). Freya Pharma Solutions plans to conduct the pivotal Phase III clinical trial with its therapy Lybrido in 516 patients across Europe to confirm the efficacy of Lybrido in women suffering from female...
Read More
, , , ,
April 19, 2021

Citryll to start first-in-human studies with CR2O as clinical operations partner

Citryll has planned the start of first in human studies for its development candidate CIT-013 for July 2021. CR2O is proud to be a part of Citryll’s exiting journey offering their services and operational expertise in early clinical development. Citryll is a private pharmaceutical company based in Oss, the Netherlands that is dedicated to the development and commercialization of therapeutics...
Read More
, , , , , ,
1 2